Moderator: Theodoros M. Mavridis (Dublin, Ireland) Guest: Messoud Ashina (Glostrup, Denmark) In this episode Theodoros M. Mavridis and Messoud Ashina delve into the findings of the Phase 2 HOPE clinical trial, which assesses the efficacy and safety of Lu AG09222, a monoclonal antibody that targets the PACAP pathway. They explore the potential of this innovative treatment for migraine prevention while highlighting the critical role of the PACAP pathway in migraine pathophysiology.
Moderator: Theodoros M. Mavridis (Dublin, Ireland)
Guest: Messoud Ashina (Glostrup, Denmark)
In this episode Theodoros M. Mavridis and Messoud Ashina delve into the findings of the Phase 2 HOPE clinical trial, which assesses the efficacy and safety of Lu AG09222, a monoclonal antibody that targets the PACAP pathway. They explore the potential of this innovative treatment for migraine prevention while highlighting the critical role of the PACAP pathway in migraine pathophysiology.